Cargando…
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604956/ https://www.ncbi.nlm.nih.gov/pubmed/37891860 http://dx.doi.org/10.3390/brainsci13101494 |
_version_ | 1785126958687846400 |
---|---|
author | Pepe, Maria Bartolucci, Giovanni Marcelli, Ilaria Pesaresi, Francesco Brugnami, Andrea Caso, Romina Fischetti, Alessia Grisoni, Flavia Mazza, Marianna Camardese, Giovanni Di Nicola, Marco Sani, Gabriele |
author_facet | Pepe, Maria Bartolucci, Giovanni Marcelli, Ilaria Pesaresi, Francesco Brugnami, Andrea Caso, Romina Fischetti, Alessia Grisoni, Flavia Mazza, Marianna Camardese, Giovanni Di Nicola, Marco Sani, Gabriele |
author_sort | Pepe, Maria |
collection | PubMed |
description | The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients’ view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with ESK-NS (mean dose: 78.4 ± 11.43 mg) for three months and evaluated at different time-points through clinician-rated and self-administered scales, assessing changes in depression, anhedonia, sleep, cognition, suicidality, and anxiety. We observed an overall early improvement that lasted over time (endpoint total score reduction in Montgomery-Åsberg Depression Rating Scale, p < 0.001, Beck Depression Inventory, p = 0.003). Patients reported a significant self-rated decrease in anhedonia at two months (Snaith–Hamilton Pleasure Scale, p = 0.04) and in suicide ideation at endpoint (BDI subitem 9, p = 0.039) vs. earlier improvements detected by clinicians (one-month reduction in MADRS subitem 8, p = 0.005, and subitem 10, p = 0.007). These findings confirm the effectiveness of a three-month treatment with ESK-NS in TRD patients, highlighting an overall overlapping response from patients’ and clinicians’ perspectives, although with some differential effects on specific symptoms at given time-points. Including patients’ viewpoints in routine assessments could inform clinical practice, ensuring a better characterization of clinical phenotypes to deliver personalized interventions. |
format | Online Article Text |
id | pubmed-10604956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106049562023-10-28 The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression Pepe, Maria Bartolucci, Giovanni Marcelli, Ilaria Pesaresi, Francesco Brugnami, Andrea Caso, Romina Fischetti, Alessia Grisoni, Flavia Mazza, Marianna Camardese, Giovanni Di Nicola, Marco Sani, Gabriele Brain Sci Article The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients’ view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with ESK-NS (mean dose: 78.4 ± 11.43 mg) for three months and evaluated at different time-points through clinician-rated and self-administered scales, assessing changes in depression, anhedonia, sleep, cognition, suicidality, and anxiety. We observed an overall early improvement that lasted over time (endpoint total score reduction in Montgomery-Åsberg Depression Rating Scale, p < 0.001, Beck Depression Inventory, p = 0.003). Patients reported a significant self-rated decrease in anhedonia at two months (Snaith–Hamilton Pleasure Scale, p = 0.04) and in suicide ideation at endpoint (BDI subitem 9, p = 0.039) vs. earlier improvements detected by clinicians (one-month reduction in MADRS subitem 8, p = 0.005, and subitem 10, p = 0.007). These findings confirm the effectiveness of a three-month treatment with ESK-NS in TRD patients, highlighting an overall overlapping response from patients’ and clinicians’ perspectives, although with some differential effects on specific symptoms at given time-points. Including patients’ viewpoints in routine assessments could inform clinical practice, ensuring a better characterization of clinical phenotypes to deliver personalized interventions. MDPI 2023-10-22 /pmc/articles/PMC10604956/ /pubmed/37891860 http://dx.doi.org/10.3390/brainsci13101494 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pepe, Maria Bartolucci, Giovanni Marcelli, Ilaria Pesaresi, Francesco Brugnami, Andrea Caso, Romina Fischetti, Alessia Grisoni, Flavia Mazza, Marianna Camardese, Giovanni Di Nicola, Marco Sani, Gabriele The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression |
title | The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression |
title_full | The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression |
title_fullStr | The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression |
title_full_unstemmed | The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression |
title_short | The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression |
title_sort | patient’s perspective on the effects of intranasal esketamine in treatment-resistant depression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604956/ https://www.ncbi.nlm.nih.gov/pubmed/37891860 http://dx.doi.org/10.3390/brainsci13101494 |
work_keys_str_mv | AT pepemaria thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT bartoluccigiovanni thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT marcelliilaria thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT pesaresifrancesco thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT brugnamiandrea thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT casoromina thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT fischettialessia thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT grisoniflavia thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT mazzamarianna thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT camardesegiovanni thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT dinicolamarco thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT sanigabriele thepatientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT pepemaria patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT bartoluccigiovanni patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT marcelliilaria patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT pesaresifrancesco patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT brugnamiandrea patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT casoromina patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT fischettialessia patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT grisoniflavia patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT mazzamarianna patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT camardesegiovanni patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT dinicolamarco patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression AT sanigabriele patientsperspectiveontheeffectsofintranasalesketamineintreatmentresistantdepression |